A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of NBI-98854 in Pediatric Subjects With Tourette Syndrome

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of NBI-98854 in Pediatric Subjects With Tourette Syndrome

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Oct 2017

At a glance

  • Drugs Valbenazine (Primary)
  • Indications Gilles de la Tourette's syndrome
  • Focus Therapeutic Use
  • Acronyms T-Force GREEN
  • Sponsors Neurocrine Biosciences
  • Most Recent Events

    • 09 Oct 2017 Status changed from active, no longer recruiting to completed.
    • 03 Aug 2017 Primary endpoint Severity of tic symptoms assessed by Yale Global Tic Severity Scale YGTSS time frame Week 6has not been met.
    • 09 May 2017 According to a Neurocrine Biosciences media release, data from the study is anticipated in May 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top